Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Select your state to see jurisdictional framework, reporting obligations, and authority links. Substance information above is the same in every state.
For prescribing by certain health practitioners Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
The condition must be stable for the prescriber to consider the listed maximum quantity of this medicine suitable for this patient. Clinical criteria: Treatment criteria: Must be treated by a health practitioner who is any of: (i) a medical practitioner, (ii) an authorised PBS prescriber who is not a medical practitioner, but who is: (a) sharing care of the patient with at least one medical practitioner; (b) intending to share care of the patient with a medical practitioner.
“Phenytoin is a hydantoin derivative which inhibits the spread of seizure activity in the motor cortex.”
“The plasma half-life is normally from 10 to 15 hours.”
“In general, phenytoin is an inducer of the hepatic cytochrome P450 microsomal enzymes including CYP3A4, CYP2D6, CYP1A2, CYP2C9 and CYP2C19 isoenzymes. Phenytoin is metabolised primarily by CYP2C9 (major) and CYP2C19 (minor), thus several drugs may inhibit or induce the metabolism of phenytoin.”
Working under the parallel aged-care framework? Aged-care equivalent →
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.